BMO Capital Markets reissued their sell rating on shares of Eli Lilly and (NYSE:LLY) in a research note released on Wednesday morning. The brokerage currently has a $74.00 price objective on the stock.
Several other equities research analysts have also weighed in on LLY. Zacks Investment Research raised Eli Lilly and from a hold rating to a buy rating and set a $85.00 target price on the stock in a research report on Tuesday. Jefferies Group reaffirmed a buy rating and issued a $91.00 target price on shares of Eli Lilly and in a research report on Friday, March 23rd. Bank of America dropped their target price on Eli Lilly and from $88.00 to $86.00 and set a neutral rating on the stock in a research report on Thursday, February 1st. TheStreet lowered Eli Lilly and from a b rating to a c rating in a research report on Monday, March 5th. Finally, Credit Suisse Group reaffirmed a hold rating and issued a $80.00 target price on shares of Eli Lilly and in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Eli Lilly and presently has an average rating of Hold and an average target price of $92.84.
LLY stock opened at $76.85 on Wednesday. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85. The company has a market cap of $86,135.91, a P/E ratio of 17.96, a PEG ratio of 1.43 and a beta of 0.26. Eli Lilly and has a 12-month low of $73.69 and a 12-month high of $89.09.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.08 by $0.06. The business had revenue of $6.16 billion for the quarter, compared to analyst estimates of $5.93 billion. Eli Lilly and had a positive return on equity of 33.01% and a negative net margin of 0.89%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the company posted $0.95 EPS. sell-side analysts expect that Eli Lilly and will post 4.87 earnings per share for the current year.
In related news, CFO Joshua L. Smiley sold 3,000 shares of the firm’s stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $79.20, for a total transaction of $237,600.00. Following the completion of the transaction, the chief financial officer now owns 20,029 shares of the company’s stock, valued at $1,586,296.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.09, for a total value of $72,981.00. Following the transaction, the insider now directly owns 4,130 shares of the company’s stock, valued at approximately $334,901.70. The disclosure for this sale can be found here. Insiders have sold 15,261 shares of company stock worth $1,225,085 over the last three months. Corporate insiders own 0.11% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Eli Lilly and by 1.2% during the fourth quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock valued at $5,393,119,000 after buying an additional 776,893 shares in the last quarter. Franklin Resources Inc. boosted its stake in Eli Lilly and by 2.7% during the fourth quarter. Franklin Resources Inc. now owns 28,519,524 shares of the company’s stock valued at $2,408,787,000 after buying an additional 754,681 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Eli Lilly and by 16.1% during the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after buying an additional 1,503,918 shares in the last quarter. Geode Capital Management LLC boosted its stake in Eli Lilly and by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 9,854,964 shares of the company’s stock valued at $830,522,000 after buying an additional 406,812 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in Eli Lilly and by 1.8% during the fourth quarter. UBS Asset Management Americas Inc. now owns 6,636,386 shares of the company’s stock valued at $560,509,000 after buying an additional 115,499 shares in the last quarter. 77.63% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/eli-lilly-ands-lly-sell-rating-reaffirmed-at-bmo-capital-markets.html.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.